Back to top
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Roche Holding AG (RHHBY) - $25 value - yours FREE >>
Johnson & Johnson (JNJ) - $25 value - yours FREE >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche Holding AG (RHHBY) - $25 value - yours FREE >>
Johnson & Johnson (JNJ) - $25 value - yours FREE >>
Image: Bigstock
Roche's Gazyva Fails in Phase III B-cell Lymphoma Study
Roche Holding AG (RHHBY - Free Report) announced disappointing results from the phase III study, GOYA, on Gazyva for previously untreated diffuse large B-cell lymphoma (DLBCL).
The global phase III, open-label, multicenter, randomized, two-arm study examined the efficacy and safety of the combination of Gazyva and CHOP chemotherapy (G-CHOP) against Rituxan plus CHOP chemotherapy (R-CHOP).
The trial failed to meet the primary endpoint of a reduction in the risk of disease worsening or death (progression-free survival) compared to Rituxan plus R-CHOP. Adverse events were consistent in both arms.
ROCHE HLDG LTD Price and EPS Surprise
ROCHE HLDG LTD Price and EPS Surprise | ROCHE HLDG LTD Quote
The results were a setback for the company as previous trials had showed that Gazyva helped people with previously untreated follicular lymphoma or chronic lymphocytic leukemia live longer without their disease worsening, compared to Rituxan, when combined with chemotherapy.
Results were disappointing also because DLBCL is the most common subtype of non-Hodgkin lymphoma (NHL).
Gazyva is already approved in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia. In Feb 2016, the FDA expanded the label of Gazyva in combination with bendamustine followed by Gazyva alone to include the treatment of follicular lymphoma in patients who did not respond to a Rituxan-containing regimen, or whose follicular lymphoma returned after such a treatment. Last month, it was approved as Gazyvaro in the EU for the same indication.
Roche’s hematology portfolio boasts approved drugs like MabThera/Rituxan, Gazyva/Gazyvaro, Tecentriq (atezolizumab) and Venclexta, as well as an encouraging pipeline comprising candidates like polatuzumab vedotin/RG7596 and a small-molecule antagonist of MDM2 (idasanutlin/RG7388).
Roche currently carries a Zacks Rank #2 (Buy). Other favorably placed stocks in the healthcare sector include Pfizer, Inc. (PFE - Free Report) , Johnson & Johnson (JNJ - Free Report) and Gilead Sciences (GILD - Free Report) . Each of these stocks carries the same rank as Roche.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>